Received Dec 22, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | 3 | UNK | — |
Patient received dose 1 on 6/27/2025. Patient received dose 2 on 8/14/2025. This schedule does not follow the current label.; This non-serious case was reported by a nurse via sales rep and described the occurrence of drug dose administration interval too short in a 18-year-old male patient who received Men B NVS (Bexsero) for prophylaxis. Previously administered products included Bexsero (received 1st dose on 27-JUN-2025) and Bexsero (received 2nd dose on 14-AUG-2025). On 17-DEC-2025, the patient received the 3rd dose of Bexsero. On 17-DEC-2025, an unknown time after receiving Bexsero, the patient experienced drug dose administration interval too short (Verbatim: Patient received dose 1 on 6/27/2025. Patient received dose 2 on 8/14/2025. This schedule does not follow the current label.). The outcome of the drug dose administration interval too short was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 17-DEC-2025 The batch number was not provided and a request for this information has been made.